Literature DB >> 27702926

Retreatment of a choroidal vein of Galen malformation with embolization 42 years after open surgical treatment in the neonatal period.

Lucas Elijovich1, Asim F Choudhri2, Adam S Arthur1, Paul Klimo1, Frederick A Boop1, Alejandro Berenstein3.   

Abstract

In 1976 an infant boy initially presented with a choroidal vein of Galen malformation (cVOGM). Craniotomy and clipping of the anterior cerebral artery and posterior choroidal arteries was performed, which was reported in the literature 40 years ago. The patient remained asymptomatic until age 42 when he re-presented with an isolated intraventricular hemorrhage. Angiography demonstrated cVOGM with venous sinus occlusive disease leading to venous hypertension and subsequent intraventricular hemorrhage. The angiogram also demonstrated a 'pseudo-nidus' composed of multiple arterial-to-arterial anastomoses that had developed as a result of the original surgical treatment. We embolized a portion of the lesion to reduce the venous hypertension. The patient has been asymptomatic for more than 2 years. To our knowledge, this is the first reported case of a symptomatic neonatal VOGM treated with open surgery that required embolization as an adult for a delayed hemorrhagic presentation. 2016 BMJ Publishing Group Ltd.

Entities:  

Keywords:  Aneurysm; Fistula; Hemorrhage; Vascular Malformation

Mesh:

Year:  2016        PMID: 27702926      PMCID: PMC5073684          DOI: 10.1136/bcr-2016-012709

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  The transtorcular embolization of vein of Galen aneurysms.

Authors:  J P Mickle; R G Quisling
Journal:  J Neurosurg       Date:  1986-05       Impact factor: 5.115

Review 2.  The management of vein of Galen aneurysmal malformations.

Authors:  Pierre L Lasjaunias; Soke M Chng; Marina Sachet; Hortensia Alvarez; Georges Rodesch; Ricardo Garcia-Monaco
Journal:  Neurosurgery       Date:  2006-11       Impact factor: 4.654

3.  Endovascular treatment of vein of Galen aneurysmal malformation: management strategy and 21-year experience in Toronto.

Authors:  Ai-Hsien Li; Derek Armstrong; Karel G terBrugge
Journal:  J Neurosurg Pediatr       Date:  2011-01       Impact factor: 2.375

Review 4.  Adult presentation of a familial-associated vein of galen aneurysmal malformation: case report.

Authors:  David S Xu; Asad A Usman; Michael C Hurley; Christopher S Eddleman; Bernard R Bendok
Journal:  Neurosurgery       Date:  2010-12       Impact factor: 4.654

Review 5.  Aneurysms of the vein of Galen: embryonic considerations and anatomical features relating to the pathogenesis of the malformation.

Authors:  C A Raybaud; C M Strother; J K Hald
Journal:  Neuroradiology       Date:  1989       Impact factor: 2.804

6.  Surgical treatment of an aneurysm of the vein of Galen in a newborn with heart failure.

Authors:  J Eiras; L I Carcavilla; J Gomez; A Goñi; J Salazar; A Marco
Journal:  Childs Nerv Syst       Date:  1985       Impact factor: 1.475

7.  Arteriovenous malformation of the vein of Galen: treatment in a neonate.

Authors:  D G Watson; R R Smith; A W Brann
Journal:  Am J Dis Child       Date:  1976-05

8.  Curative embolization of cerebral arteriovenous malformations (AVMs) with Onyx in 101 patients.

Authors:  Vasilios Katsaridis; Chrysanthi Papagiannaki; Enrico Aimar
Journal:  Neuroradiology       Date:  2008-04-12       Impact factor: 2.804

9.  The use of Onyx for embolization of central nervous system arteriovenous lesions in pediatric patients.

Authors:  R Thiex; A Williams; E Smith; R M Scott; D B Orbach
Journal:  AJNR Am J Neuroradiol       Date:  2009-09-12       Impact factor: 3.825

  9 in total
  1 in total

1.  Superselective transvenous embolization with Onyx and n-BCA for vein of Galen aneurysmal malformations with restricted transarterial access: safety, efficacy, and technical aspects.

Authors:  Kirill Orlov; Anton Gorbatykh; Vadim Berestov; Timur Shayakhmetov; Dmitry Kislitsin; Pavel Seleznev; Nikolay Strelnikov
Journal:  Childs Nerv Syst       Date:  2017-07-08       Impact factor: 1.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.